Original Research

DOI: 10.4244/EIJ-D-25-00034

Impact of intracoronary supersaturated oxygen therapy on microvascular obstruction and infarct size in patients with acute anterior myocardial infarction

Tobias König1, MD; Dominik Berliner1, MD; Johanna Diekmann2, MD; Muharrem Akin1, MD; Tobias Pfeffer1, MD; Carolina Sanchez Martinez1, MSc; Vera Garcheva1, MD; Frank M. Bengel2, MD; Johann Bauersachs1, MD; Andreas Schäfer1, MD

Abstract

Background: Final infarct size (FIS) and microvascular obstruction (MVO) are associated with heart failure hospitalisations and mortality in patients with acute myocardial infarction (AMI). Interventions beyond primary percutaneous coronary intervention (PCI) to reduce FIS are needed. Supersaturated oxygen (SSO2) therapy demonstrated reduced FIS in clinical trials.

Aims: We aimed to investigate whether routine use of SSO2 reduces FIS and MVO in clinical practice.

Methods: Intracoronary SSO2 was delivered for 60 minutes after successful primary PCI in patients with anterior AMI. Results from 20 SSO2 patients were compared with those from 20 similar non-SSO2 AMI patients. Multimodal imaging including single-photon emission computed tomography (SPECT), fibroblast activation protein inhibitor positron emission tomography (FAPI-PET), and cardiac magnetic resonance imaging (CMR) was performed to assess left ventricular function, FIS, area at risk, extent of myocardial fibroblast activation, myocardial salvage, and MVO.

Results: The two groups did not significantly differ regarding sex, age, weight, hypertension, dyslipidaemia, smoking and diabetes status, prehospital cardiac arrest, door-to-balloon time, Thrombolysis in Myocardial Infarction flow before and after PCI, or renal function (p>0.1 for each) and had comparable area at risk by CMR and FAPI-PET. SSO2 patients showed lower FIS determined by CMR (SSO2: 20% vs non-SSO2: 32%; p<0.001) and SPECT (SSO2: 16% vs non-SSO2: 29%; p=0.014). Myocardial salvage was higher in SSO2 patients (50% vs 28%; p=0.002). MVO occurred less often and was less extreme under SSO2 therapy.

Conclusions: SSO2 therapy was associated with significantly reduced microvascular obstruction and FIS in patients with anterior AMI in clinical routine practice.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 14
Jul 21, 2025
Volume 21 Number 14
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00031 Jul 21, 2025
Supersaturated oxygen therapy to reduce myocardial infarct size: time to pay attention!
Stone G and Akinmolayemi O
free

CLINICAL RESEARCH

10.4244/EIJ-D-16-00818 Aug 4, 2017
Microvascular dysfunction following ST-elevation myocardial infarction and its recovery over time
Hassell M et al
free

Clinical research

10.4244/EIJ-D-20-01421 Dec 17, 2021
Near-infrared spectroscopy to predict microvascular obstruction after primary percutaneous coronary intervention
Terada K et al
free

Viewpoint

10.4244/EIJ-D-22-00250 Aug 19, 2022
Low-dose fibrinolysis during primary percutaneous intervention for preventing no-reflow: stepping back to move forward?
Pelliccia F and Niccoli G
free
Trending articles
225.25

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.05

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved